Quest Partners LLC Invests $261,000 in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

Quest Partners LLC bought a new position in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 4,104 shares of the specialty pharmaceutical company’s stock, valued at approximately $261,000.

A number of other institutional investors and hedge funds have also modified their holdings of the stock. Great Lakes Advisors LLC increased its stake in shares of ANI Pharmaceuticals by 10.6% during the second quarter. Great Lakes Advisors LLC now owns 56,081 shares of the specialty pharmaceutical company’s stock worth $3,571,000 after purchasing an additional 5,359 shares in the last quarter. Arizona State Retirement System grew its stake in ANI Pharmaceuticals by 4.7% during the 2nd quarter. Arizona State Retirement System now owns 4,702 shares of the specialty pharmaceutical company’s stock valued at $299,000 after acquiring an additional 211 shares in the last quarter. Rhumbline Advisers grew its stake in ANI Pharmaceuticals by 15.4% during the 2nd quarter. Rhumbline Advisers now owns 42,170 shares of the specialty pharmaceutical company’s stock valued at $2,685,000 after acquiring an additional 5,617 shares in the last quarter. Natixis Advisors LLC purchased a new stake in ANI Pharmaceuticals during the 2nd quarter valued at about $741,000. Finally, Hussman Strategic Advisors Inc. increased its holdings in shares of ANI Pharmaceuticals by 33.3% in the second quarter. Hussman Strategic Advisors Inc. now owns 42,000 shares of the specialty pharmaceutical company’s stock valued at $2,675,000 after purchasing an additional 10,500 shares during the last quarter. Hedge funds and other institutional investors own 76.05% of the company’s stock.

Insider Activity at ANI Pharmaceuticals

In related news, SVP Chad Gassert sold 20,000 shares of the business’s stock in a transaction on Monday, July 1st. The stock was sold at an average price of $63.44, for a total value of $1,268,800.00. Following the sale, the senior vice president now owns 193,226 shares in the company, valued at approximately $12,258,257.44. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In related news, SVP Chad Gassert sold 20,000 shares of the business’s stock in a transaction on Monday, July 1st. The stock was sold at an average price of $63.44, for a total value of $1,268,800.00. Following the sale, the senior vice president now owns 193,226 shares in the company, valued at approximately $12,258,257.44. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, COO Muthusamy Shanmugam sold 14,257 shares of the business’s stock in a transaction on Wednesday, July 17th. The stock was sold at an average price of $63.16, for a total value of $900,472.12. Following the transaction, the chief operating officer now directly owns 635,363 shares of the company’s stock, valued at $40,129,527.08. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 65,757 shares of company stock worth $4,075,585. 12.70% of the stock is currently owned by company insiders.

ANI Pharmaceuticals Stock Performance

Shares of ANI Pharmaceuticals stock opened at $58.51 on Friday. The firm has a market cap of $1.23 billion, a PE ratio of 36.57 and a beta of 0.71. The company has a quick ratio of 3.07, a current ratio of 3.97 and a debt-to-equity ratio of 0.62. ANI Pharmaceuticals, Inc. has a 52 week low of $48.20 and a 52 week high of $70.81. The business’s fifty day simple moving average is $61.39 and its 200-day simple moving average is $63.88.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its earnings results on Tuesday, August 6th. The specialty pharmaceutical company reported $1.02 EPS for the quarter, beating analysts’ consensus estimates of $0.95 by $0.07. The company had revenue of $138.00 million for the quarter, compared to analysts’ expectations of $129.09 million. ANI Pharmaceuticals had a net margin of 5.01% and a return on equity of 15.64%. ANI Pharmaceuticals’s revenue for the quarter was up 18.5% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.06 earnings per share. Equities analysts forecast that ANI Pharmaceuticals, Inc. will post 3.5 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on ANIP shares. StockNews.com lowered ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, September 7th. Truist Financial reissued a “hold” rating and set a $60.00 price target (down previously from $80.00) on shares of ANI Pharmaceuticals in a research report on Wednesday. Finally, HC Wainwright restated a “buy” rating and set a $94.00 price objective on shares of ANI Pharmaceuticals in a research report on Wednesday, August 7th. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $77.75.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.